Compare Neurocrine Biosciences Inc (NBIX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Quantumscape Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Quantumscape Corp trades at $4.64 (market cap $2.78B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.3× Quantumscape Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Quantumscape Corp for 37 Days on average.
| NBIX | QS | |
|---|---|---|
Market Cap | $14.60B | $2.78B |
Volume | 1,075,694 | 11,236,221 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $18.44 |
52-Week Low | $123.10 | $4.52 |
Typical Hold Time | 23 Days | 37 Days |
Enterprise Value | $14.61B | $1.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
QuantumScape (QS) trades at $4.58, down 1.51% on the day, with a bearish technical outlook and no current revenue generation. The company reported a net loss of $435.05 million in 2025 and faces significant execution risks as it develops solid-state battery technology. Analyst sentiment is cautious with 73% hold ratings, though the consensus price target of $10.35 suggests potential upside if commercialization milestones are met.
QS represents a high-risk, high-reward opportunity in the pre-revenue EV battery space. The primary investment thesis hinges on successful commercialization of solid-state batteries by 2029, but competition and execution delays pose substantial risks. Current negative ROE of -39.08% and cash burn require careful monitoring of funding runway and partnership developments with automotive manufacturers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
